InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Targeting Confirmatory Support for Existing ALS Trial Data with NIH-Funded EAP Study
December 1, 2023
Clene’s (NASDAQ: CLNN) wholly owned subsidiary Clene Nanomedicine Inc. and its collaborators, Columbia University and Synapticure, recently received a four-year grant totaling $45.1 million. The grant will support an Expanded Access Protocol (“EAP”) study investigating the safety and efficacy of Clene’s investigational product (“IP”), CNM-Au8, as a treatment for people with amyotrophic lateral sclerosis (“ALS”). […]
Clene Inc. (NASDAQ: CLNN) Capitalizing on the Promising Chemical and Therapeutic Properties of Nanocrystals to Address High Unmet Medical Needs
November 22, 2023
Nanotechnology has attracted a great deal of the scientific community’s attention thanks to its ability to deliver medicinally attractive nanoparticles (“NPs”) with promising performances that are directly attributable to such properties as ease of cellular uptake, stability, solubility, synthetic accessibility, and release pattern and cell penetration. Studies investigating the therapeutic capabilities of metallic NPs such […]
Clene Inc. (NASDAQ: CLNN) Reports Q3 2023 Financial Results, Recent Operating Highlights for Its ALS Clinical Program
November 16, 2023
Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of a pipeline of novel clean-surfaced nanotechnology therapeutics for the treatment of central nervous system disorders, including Amyotrophic Lateral Sclerosis (“ALS”), multiple sclerosis (“MS”), and Parkinson’s disease (“PD”), recently released its financial results […]
Clene Inc. (NASDAQ: CLNN) Among Grant Awardees Selected to Advance Scientific Research on ALS
November 10, 2023
In late December of 2021, President Biden signed into law H.R. 3537, the Accelerated Access to Critical Therapies for ALS Act (“Act for ALS”) (https://ibn.fm/oQbSk). The Act for ALS (amyotrophic lateral sclerosis), now public law, directs the Department of Health and Human Services through the Secretary to, among others, “award grants to participating entities for […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Q3 2023 Financial Results, Operating Highlights
November 7, 2023
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., today released its third quarter 2023 financial results and provided recent operating highlights for its ALS clinical program. Among the highlights, the company reported statistically significant improved survival benefit of 19.3 months and significantly delayed clinical worsening in patients […]
Clene Inc. (NASDAQ: CLNN) Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis; Announces Peer-Reviewed Study
October 30, 2023
Amyotrophic lateral sclerosis (“ALS”), or Lou Gehrig’s disease, is a progressive and degenerative neuromuscular disease that destroys nerve cells known as motor neurons, which control voluntary muscle movement (https://ibn.fm/bgJGu). A fatal neurological disorder, ALS lowers the life expectancy of patients to two to five years post-diagnosis, although some patients may live longer, as was the […]
Clene Inc. (NASDAQ: CLNN) Announces Four-Year Grant to Support Expanded Access Protocol for CNM-Au8 From NINDS
October 25, 2023
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company on a mission to transform the treatment of neurodegenerative diseases, recently announced that its wholly-owned subsidiary Clene Nanomedicine Inc., in collaboration with Columbia University and Synapticure, has been awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (“NINDS”). The grant […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) ‘Innovates’ Investigational Drug with Patented Nanotechnology
October 17, 2023
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, announced that it has innovated its investigational drug, CNM-Au8(R), with nanotechnology. Clene is evaluating CNM-Au8(R) for the treatment of neurodegenerative disease, and the innovation reflects the growing importance of nanotechnology in the drug space. […]
Clene Inc. (NASDAQ: CLNN) Applies Patented Nanotechnology to Development of CNM-Au8(R), its Investigational Drug for ALS
October 16, 2023
October 2023 has turned into a month for the celebration of nanotechnology. On Wednesday, Oct. 4, 2023, three U.S.-based scientists, Moungi Bawendi, Louis Brus, and Aleksey Ekimov, were awarded the 2023 Nobel Prize in Chemistry for their discovery and synthesis of tiny clusters of atoms known as quantum dots, which are widely used today in […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Featured in Latest Episode of The Bell2Bell Podcast
October 10, 2023
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, is featured in the latest Bell2Bell Podcast release. During the segment, podcast host Stuart Smith discusses the company with Clene president and CEO Rob Etherington, who explains Clene’s business model and provides an overview […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces $45.1M NINDS Grant to Support Expanded Access Protocol for CNM-Au8(R) in ALS
October 5, 2023
Clene (NASDAQ: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc. in collaboration with Columbia University and Synapticure, was awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (“NINDS”), a division of the National Institutes of Health (“NIH”). The grant is to support an Expanded Access Protocol (“EAP”) […]
Unveiling the Neuroprotective Power of CNMAu8 A Promising Breakthrough in Neurodegenerative Disease Treatment
September 29, 2023
by Elaine Mendonça On September 28, 2023, Clene Inc. (NASDAQ: CLNN) made an exciting announcement regarding their groundbreaking research on the investigational drug CNM-Au8. In a scientific paper published in the esteemed journal Small, Clene Inc. revealed the catalytic mechanism of action behind the therapeutic properties of CNM-Au8. The study showcased the remarkable neuroprotective abilities of CNM-Au8, attributing […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Investigational Drug Focus of Study Published in Peer-Reviewed Journal
September 28, 2023
Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis, announced the publication of a scientific paper. The paper, which was published in the “Small” journal, describes […]
Clene Inc. (NASDAQ: CLNN) Is ‘One to Watch’
September 28, 2023
Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s disease, and multiple sclerosis (“MS”). Its lead drug candidate is CNM-Au8(R), an oral suspension developed to restore neuronal health and function by increasing energy production and utilization […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation at Upcoming Cantor Fitzgerald Annual Global Healthcare Conference
September 26, 2023
Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis, will be represented at this week’s Cantor Fitzgerald Annual Global Healthcare Conference. According to the company, CEO […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Releases Significant Long-Term Survival Improvement Data from ALS Trial
September 25, 2023
Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc. are reporting on long-term follow-up data for participants in the HEALEY ALS Platform Trial; patients in the study were treated with CNM-Au8(R) 30mg for up to 133 weeks. According to the announcement, data from 59 patients shows prolonged life with 49% decreased risk of […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces $40M Public Offering
June 22, 2023
Clene (NASDAQ: CLNN), along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, recently announced the pricing of an underwritten public offering. The offering consists of 50,000,000 shares of its common stock and two tranches of warrants (each warrant to […]
ROTH Capital Partners to Host Inaugural Healthcare Opportunities Conference on October 6th at the Yale Club in New York City
October 4, 2022
NEWPORT BEACH, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) — via InvestorWire — ROTH Capital Partners (ROTH), www.roth.com, a full service investment bank focused on serving emerging growth companies and their investors, today announced that it will host its Inaugural Healthcare Opportunities Conference in New York City, NY on October 6th, 2022. The conference will provide pre-qualified institutional investors and healthcare […]
Clene Inc. (NASDAQ: CLNN) Featured in Virtual Coverage of the 33rd Annual ROTH Conference
March 16, 2021
Clene Inc. (NASDAQ: CLNN), a clinical-stage biopharmaceutical company focused on neurodegenerative disease, has innovated a novel nanotherapeutics platform to create a new class of drugs—bioenergetic nanocatalysts. Clene’s lead drug candidate, CNM-Au8, is a the concentrated nanocrystalline gold (Au) suspension that drives critical cellular bioenergetic reactions in the CNS. CNM-Au8 increases cellular energy to accelerate neurorepair […]